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ABSTRACT
Objective To examine the effectiveness of methods to
improve partner notification by patient referral (index
patient has responsibility for informing sex partners of
their exposure to a sexually transmitted infection).
Design Systematic review of randomised trials of any
intervention to supplement simple patient referral.
Data sources Seven electronic databases searched
(January 1990 to December 2005) without language
restriction, and reference lists of retrieved articles.
Reviewmethods Selection of trials, data extraction, and
quality assessment were done by two independent
reviewers. The primary outcome was a reduction of
incidence or prevalence of sexually transmitted
infections in index patients. If this was not reported data
were extracted according to a hierarchy of secondary
outcomes: number of partners treated; number of
partners tested or testing positive; and number of
partners notified, located, or elicited. Random effects
meta-analysis was carried out when appropriate.
Results 14 trials were included with 12 389 women and
men diagnosed as having gonorrhoea, chlamydia, non-
gonococcal urethritis, trichomoniasis, or a sexually
transmitted infection syndrome. All studies had
methodological weaknesses that could have biased
their results. Three strategies were used. Six trials
examined patient delivered partner therapy. Meta-
analysis of five of these showed a reduced risk of
persistent or recurrent infection in patients with
chlamydia or gonorrhoea (summary risk ratio 0.73, 95%
confidence interval 0.57 to 0.93). Supplementing
patient referral with information for partners was as
effective as patient delivered partner therapy. Neither
strategy was effective in women with trichomoniasis.
Two trials found that providing index patients with
chlamydia with sampling kits for their partners
increased the number of partners who got treated.
Conclusions Involving index patients in shared
responsibility for the management of sexual partners
improves outcomes. Health professionals should
consider the following strategies for the management of
individual patients: patient delivered partner therapy,
home sampling for partners, and providing additional
information for partners.
INTRODUCTION
Partner notification is an important part of managing
sexually transmitted infections.1 This includes identi-
fying sex partners, informing them of their exposure,
ensuring evaluation or treatment, and providing
advice on preventing further infections.2 The stigma
attached to sexually transmitted infections makes
partner notification difficult.3 More partners are
likely to be treated if a health professional contacts
them on behalf of the patient (provider referral) than
if patients do this themselves (patient referral).4 In
practice, however, both patients5 and doctors6 prefer
patient referral,which is cheaper6-8 and easier to do in
primary care, where increasing numbers of sexually
transmitted infections are being diagnosed.9 Current
methods of patient referral only reach 40-60% of
named sexual partners,10 so new strategies are
needed.
The National Institute for Health and Clinical
Excellencewill provide guidance about interventions
to reduce the transmission of sexually transmitted
infections, including partner notification, in February
2007 (www.nice.org.uk). Because none of the pub-
lished systematic reviews of partner notification
included new methods to improve patient
referral4 11 12 we systematically reviewed the litera-
ture to examine their effectiveness.
METHODS
We searched seven electronic databases without lan-
guage restrictions from January 1990 to December
2005 (Medline, Embase, Cinahl, Cochrane Library,
PsycINFO, Sigle, DARE) and the reference lists of
relevant reports. Subject headings and free text
words covering specific sexually transmitted infec-
tions were combined with terms for partner notifica-
tion (detailed search strategy available from the
authors). We also searched two electronic research
registers (international standard randomised con-
trolled trial number and clinicaltrials.gov) using the
search term “partner notification”.
We considered all sexually transmitted infections.
We included trials that compared simple patient
referral with patient referral supplemented by
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methods aimed at improving its effectiveness. We
defined simple patient referral as an intervention in
which the indexpatient had responsibility for inform-
ing their sexual partners about the infection and
advising them to seek treatment. This could be done
with or without contact cards, which are given by
index patients to partners and contain the diagnosis
and address of the clinic.
Two authors independently screened titles and
abstracts. If eligibility could not be assessed we
obtained a full text version. Disagreements were
resolved by discussion. Duplicate reports were iden-
tified and data extracted from the most recent publi-
cation.
Data on setting, participants, interventions, out-
comes, and quality were independently extracted by
two authors using a piloted, standardised form. We
used published checklists to assess methodological
quality.13 Disagreements were resolved by discus-
sion.
Outcome measures
We defined the primary outcome as a reduction of
incidenceor prevalenceof sexually transmitted infec-
tions in index patients. This is the most objectively
measured outcome and is directly related to the pub-
lic health aim of controlling the spread of sexually
transmitted infections. If the primary outcome was
not reported we extracted data according to a hierar-
chy of secondary, intermediate outcomes: number of
partners treated; number of partners tested or testing
positive; and number of partners notified, located, or
elicited.
Statistical analysis
For outcomes reported as proportions we calculated
exact 95% confidence intervals or two sided P values.
For outcomes reported as mean numbers per index
case we did not carry out additional calculations
because we could not account for the clustering of
the data. When more than two trials examined the
same interventionwe combined results using random
effects meta-analysis.14 Statistical evidence of hetero-
geneity was assessed using Cochran’s Q and the I2
statistic,which describes the percentage of total varia-
tion across trials that is attributable to heterogeneity
rather than chance.15 I2 values of 25%, 50%, and 75%
correspond to low,moderate, and high heterogeneity
between trials. Inmeta-analyseswith at least five trials
we examined funnel plots and did a statistical test for
small study effects.16 We used Stata 9.2 for all ana-
lyses.
RESULTS
Overall, 2493 unique references were identified and
290 full text manuscripts retrieved, including two
reports from unpublished studies (fig 1).w13w14 Four-
teen trials examining 16 interventions in 12 389 peo-
ple were included. Included trials studied patients
with gonorrhoea, chlamydia, trichomoniasis, non-
specific urethritis, or syndromically diagnosed infec-
tions (table; a more detailed table of the included stu-
dies is available from the authors on www.ispm.ch/
index.php?id=1193). We found no relevant trials on
syphilis,HIV, or other infections.We identified three
strategies for improving the yield of patient referral.
Six trials evaluated interventions in which the index
case was given drugs or a prescription for their part-
ners (patient delivered partner therapy).w1-w6 Two of
these also compared patient delivered partner ther-
apy with additional information for index patients to
give to partners.w1w2 Two trials evaluated providing
index patients diagnosed as having chlamydia with
sampling kits for partners.w7w8 Eight trials evaluated
providing additional written, visual, or verbal
information. w7w8w9-w14 Four trials were carried out
in African countries,w5w9w10w14 two in Denmark, w7
w8 and eight in the United States.w1-w4w6w11-w13
Methodological quality
All included studies had methodological weaknesses
that could have biased their results (see table of qual-
ity assessment on www.ispm.ch/index.php?
id=1193). Only four trial reports described an ade-
quate method of generating a random allocation
sequence,w1w5w9w10 and concealment was adequate
in only one of these.w9One other trial concealed allo-
cation by using sealed, opaque, sequentially num-
bered envelopes.w4 Two trials used systematic alloca-
tion sequences (date of birthw7 and month of
presentationw2) that could not be concealed. One
trial was described as an observational cohort, in
which women were randomly assigned to different
healthcare providers.w6No descriptionwas provided
of sequence generation or allocation concealment.
No other trial described the concealment of
allocation.w3w6w8w11-w14 Six trials measured our pre-
defined primary outcome.w1-w4w6w13 Five of these
also measured at least one secondary outcome.w1-w4
w13 Of trials measuring only secondary outcomes,
three assessed the numbers of partners treated,w5w11
References identified (n=2493)
Title and abstract screening
Excluded (n=2203):
  Duplicates (n=654)
  Topic not relevant (n=1429)
  Study design not relevant (n=76)
  Other (n=44)
Full manuscripts retrieved (n=290)
Trials included in review (n=14)
Full text assessment
Excluded (n=276):
  Duplicates (n=4)
  Topic not relevant (n=7)
  Study design not relevant (n=264)
  Other (n=1)
Fig 1 | Flowchart of trial selection
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w14 three measured numbers of partners tested,w7w8
w12 and two measured numbers of partners
notified.w9w10 Assessment of outcomes was poten-
tially biased in all but one study that used blinded
ascertainment.w14 In addition, patients in the inter-
vention but not the control group were refunded
their transport fare, and outcomes in the two groups
were assessed differently in one trial.w5 In another
two trials examining patient delivered partner ther-
apy, the wording of the question assessing the out-
come would have underestimated the proportion of
partners treated in the control groups.w1w2 In six
trials,w1-w5w9 in addition to the intervention itself par-
ticipants in the experimental group received materi-
als or benefits that could have contributed to the
observed effect.
Patient delivered partner therapy
Over 6000 patients (4912 women, 1807 men) were
enrolled in six trials of patient delivered partner
therapy.w1-w6 In one trial from Uganda,w5 and one
from the United States,w6 index patients in the inter-
vention group received packets containing only the
drugs. In the other trials packets also contained infor-
mation on the drugs and details of how to contact
health professionals.w1-w4 One trial also included
information about the infection,w4 and one included
condoms with the other materials.w3 The control
groups received simple patient referral without con-
tact cards in three trialsw1-w3 andwith contact cards in
three trials.w4-w6
The rate of persistent or recurrent infections in
patientsmanagedwith patient delivered partner ther-
apy was lower than in controls among index cases
with chlamydia or gonorrhoeabut notwith trichomo-
nas. In five trials providing sufficient data the sum-
mary risk ratio compared with simple patient referral
was 0.73 (95% confidence interval 0.57 to 0.93), with
some evidence of statistical heterogeneity (I2 37%,
P=0.18; fig 2).w1-w4w6 If 10% of patients managed
Characteristics of included studies ordered according to publication date
Study reference Participants Interventions No of patients Primary outcome and results
Kissinger et al 2006w1 Women with Trichomonas vaginalis Intervention 1, patient delivered partner therapy;
intervention 2, patient referral plus information for
partner; control, patient referral
463 Persistent or recurrent infections: intervention 1
9.4%; intervention 2 9.0%; control 6.3%; P=0.64
Golden et al 2005w3 Men and women with Neisseria
gonorrhoeae or Chlamydia
trachomatis
Intervention: patient delivered partner therapy;
control, patient referral
2751 Persistentor recurrent infections: intervention10%;
control 13%; P=0.04
Kissinger et al 2005w2 Men with N gonorrhoeae or C
trachomatis
Intervention 1, patient delivered partner therapy;
intervention 2, patient referral plus information for
partner; control, patient referral
977 Persistent or recurrent infections: intervention 1
6%; intervention 2 5%; control 12%; P< 0.01
Schillinger et al 2003w4 Women with C trachomatis Intervention: patient delivered partner therapy;
control, patient referral
1889 Persistentor recurrent infections: intervention12%;
control 15%; P=0.11
Ostergaard et al 2003w8 Men and women with C trachomatis Intervention: patient referral plus home sampling;




Partners testedper index patient:men–intervention
0.16, control 0.04; P< 0.0001; women–intervention
0.31; control 0.14; p< 0.0001
Moyo et al 2002w9 Men and women with syndromic
bacterial sexually transmitted
infections
Intervention: patient referral plus interactive
questions and answers* plus voucher for health
care; control: patient referral (unclear, 30 minute
interview)
272 Proportion with ≥ 1 partner notified: intervention
92%; control 67%; P< 0.001
Nuwaha et al 2001w5 Men and women with syndromic
sexually transmitted infections
Intervention: patient delivered partner therapy;
control: patient referral
383 Partners treated or referred per partner elicited:
intervention74%; control 34%; risk ratio 2.44 (95%
confidence interval 1.95 to 3.07)
Kissinger et al 1998w6 Women with C trachomatis Intervention: patient delivered partner therapy;
control: patient referral
256 Persistentor recurrent infections: intervention12%;
control 22%; P< 0.05
Andersen et al 1998w7 Women with C trachomatis Intervention: patient referral plus home sampling;
control: patient referral plus sampling kit to take to
healthcare provider
96 Partners tested positive per index patient:
intervention 0.27; control 0.14; difference 0.13
(95% confidence interval −0.03 to 0.29)
Faxelid et al 1996w10 Men and women with sexually
transmitted disease
Intervention: patient referral plus interactive
questions and answers* plus education†; control:
usual care (no other details)
396 Proportion with ≥ 1 partner notified: men:
intervention 100%; control 93%; P=0.001; women:
intervention 72%; control 56%; P=0.14
Katz et al 1988w11 Men with non-gonococcal urethritis Intervention: patient referral plus interactive
questions and answers* plus education†; control:
patient referral
457 Partners treated per index patient: intervention
0.22; control0.18;difference0.04(95%confidence
interval −0.04 to 0.12)
Solomon and DeJong
1988w12
Men with N gonorrhoeae Intervention: patient referral plus education†;
control: patient referral
902 Partners tested: “no significant difference”
Cleveland 2001w13 Men andwomenwithNgonorrhoeae Intervention: patient referral plus interactive
questions and answers* plus education†; control:
patient referral
1266 Persistent or recurrent infections: intervention 6%;
control 8%; P=0.76
Ellison et al 2001w14 Sex unclear; syndromic sexually
transmitted infections
Intervention 1: patient referral plus education†;
intervention 2: patient referral plus interactive
questions and answers; intervention 3: patient
referral plus interactive questions* and answers
plus education†; control: patient referral
1719 Partners treated per index patient: intervention 1
0.20; intervention 2 0.22; intervention 3 0.25;
control 0.18
Results are presented according to primary analysis presented in report (P values or confidence intervals calculated if not reported and enough details reported). Differences do not
necessarily add up owing to rounding. For additional details see table provided by authors on www.ispm.ch/index.php?id=1193.
*Interactive questions and answers include all interventions described as counselling or discussions with patients.
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with simple patient referral had persistent or recur-
rent infections, the absolute risk reduction would be
3.7% (0.7% to 4.3%) and the number needed to treat
would be 27 (23 to 143). No statistical evidence was
found for small study effects (P=0.91). Four trials pro-
vided enough details for meta-analysis of the propor-
tionofpartners treatedperpartnerelicited.w1-w3w5All
four trials favouredpatient deliveredpartner therapy,
and the meta-analysis showed a relevant increase in
the number of partners treated (risk ratio 1.44, 95%
confidence interval 1.12 to 1.86), but statistical het-
erogeneity was high (I2 94%, P < 0.0001; fig 2). The
relatively large size of trials results in small standard
errors, which can inflate the I2 statistic.
Two trials comparedpatientdelivered therapywith
patient referral supplemented by booklets with tear-
out cards and treatment guidelines for index patients
to give to partners.w1w2 The proportions of index
patients with persistent or recurrent infection with
chlamydia, gonorrhoea, or trichomonas were similar
in the two groups in both trials but data were insuffi-
cient for meta-analysis (see table of included studies
on www.ispm.ch/index.php?id=1193). The propor-
tion of partners treated was higher in patients receiv-
ing patient delivered partner therapy (summary risk
ratio 1.25, 95% confidence interval 1.15 to 1.37; I2
0%, P=0.44; fig 3).
Home sampling
Both trials onhomesamplingwere carriedout among
patients with chlamydia inDenmark.w7w8 The earlier
trial included 96 women.w7 In the larger trial, 1826
patients were randomised but only 562 (414 women
and 148 men) consented.w8 Index patients in the
intervention groups received sterile containers, infor-
mation on how to collect specimens, and a prepaid
envelope. They were advised to give the kits to sex
partners, who could collect specimens at home and
mail them to the laboratory. Patients in the control
group were instructed to tell their partners to take
the sampling kit to their doctor. In both trials home
sampling increased thenumber of partners tested and
the number of identified infected partners (table). On
the basis of the results of the larger trialw8 8 (95% con-
fidence interval, 7 to 11) index patients would need
sampling kits to have one additional index patient
with at least one partner tested.
Providing additional information
Eight trials enrolleda total of6452patients.w1w2w9-w14
Two trials in the United States (1440 patients) com-
pared the provision of additional information for
index cases to give to their partners with simple
patient referral (table).w1w2 One enrolled men with
gonorrhoea or chlamydiaw2 and the other studied
women with trichomoniasis.w1 The other six trials
evaluated different forms of information for the
index patient only. Of these, three (2387 patients) in
resourcepoorcountries studiedwomenandmenwith
a variety of laboratory or syndromically diagnosed
infections.w9w10w14 Three studies in theUnited States
enrolled 2625menwith gonorrhoea or non-gonococ-
cal urethritis.w11-w13 Four trials used simple patient
referral without a contact card,w1w2w10w11 three used
patient referral with contact cards,w12-w14 and in two
trials the control intervention was not
standardisedw10 or was unclear.w9 Outcome assess-
ments included follow-up interviews with index
patientsw1w2w9w10 and counting of partners attending
the trial centre but not other clinics.w11-w14
The types of additional information were cate-
gorised as written information to be given to
partnersw1w2; information for index cases provided
through counselling or discussion (interactive ques-
tion and answer sessions)w9w14; structured verbal
education for index patients, such as being read a
script or being asked to watch a videow12w14; and
combinations of information types.w10-w13
Written information for partners
In one trial 348 men with gonorrhoea or chlamydia
receivedbookletswith tear-out cards providing infor-
mation for partners and treatment guidelines for
health professionals in addition to simple patient
referral, and 285 controls received simple patient
referral.w2 The proportion of persistent or recurrent
infections among index patients with chlamydia or
gonorrhoea who received additional information
Kissinger et al 1998w6
Schillinger et al 2003w4
Golden et al 2005w3
Kissinger et al 2005w2
Kissinger et al 2006w1
Overall (I 2=37%, P=0.18)
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Fig 2 | Randomeffectsmeta-analyses of primary and secondary outcomes of trials comparing
patient delivered partner therapywith simple patient referral. All trials except for Schillinger et al
2003w4 had unclear or inadequate concealment of allocation
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was lower than in controls (5% v 12%; P < 0.01; risk
ratio 0.37, 95% confidence interval 0.21 to 0.66), and
partners were treated more often in the group who
received additional information for partners (46% v
35% of partners; P < 0.01; risk ratio 1.30, 1.13 to
1.49). The other trial examined the same interven-
tions in womenwith trichomonas: 154 received addi-
tional information for their partners and 155 received
simple patient referral.w1 Rates of persistent or recur-
rent infection in index patientswere similar (9% v 6%;
P=0.64; risk ratio 1.42, 0.59 to 3.41). Fewer index
patients in the group receiving the booklet than in
the control group reported that their partners had
taken the treatment (58% v 70%; P < 0.01; risk ratio
0.82, 0.69 to 0.98). No meta-analysis was carried out
on the results of these two trials.
Interactive question and answer session for index cases
One trial in South Africa found no additional benefit
in numbers of partners treated comparedwith patient
referral with contact cards.w14One trial in Zimbabwe
supplementedan interactivequestionandanswer ses-
sionwith a healthcare voucher for partners and found
statistical evidence of benefit in the number of index
patients with at least one partner notified (92% v 67%;
P < 0.001).w9
Structured verbal education or video
Two trials that evaluated information given from a
structured script or asked patients to watch a video
found no effect on partners tested or treated com-
pared with patient referral with contact cards.w12w14
Combinations
One trial inZambia found that a greater proportionof
index patients receiving one to one counselling and
contact cards with information about the importance
of seeking care had at least one partner notified com-
pared with the control group.w10 Another trial in
South Africa showed that more partners were treated
per index patient in an experimental group receiving
both standardised verbal health education messages
and individual counselling compared with patient
referral with contact cards.w14 The other trials found
no differences between experimental interventions
and patient referral with or without contact cards on
various outcomes (table).w11w13 The outcomes
reported were too different to permit meta-analysis.
Adverse effects
Only two trials, both studying syndromically diag-
nosed infections, reported adverse effects of partner
notification.w5w9 In the trial from Zimbabwe,w9 the
authors stated thatnodifferenceswere foundbetween
groups (see table of included studies on www.ispm.
ch/index.php?id=1193).The trial fromUgandacom-
pared patient delivered partner therapy with simple
patient referral.w5 Overall, around 10% of patients
reported quarrelling, with no difference between
groups. This analysis was not based on the intention
to treat population and substantially more dropouts
were from the control group.
DISCUSSION
This systematic review summarised studies of new
strategies that involve patients with sexually trans-
mitted infections in shared responsibility for the
care of their sexual partners. Five trials of patient
delivered partner therapy reported effects on persis-
tent or recurrent infections in index patients.w1-w4w6
w13 Patient delivered partner therapy was superior to
patient referral with or without contact cards, but the
absolute effects were modest. Patient delivered part-
ner therapy did not, however, reduce persistent or
recurrent infections in indexpatientswhen compared
with simple patient referral supplemented by infor-
mation for partners.w1w2 Two trials found that offer-
ing home sampling kits to partners resulted in more
partners being tested compared with sampling at a
doctor’s surgery,w7w8 but the control intervention
was not comparable to that used in other studies. Sev-
eral trials examined different ways of providing addi-
tional information to index patients. Interventions
that combine additional written and verbal informa-
tion might be superior to simple patient referral
alone.w10w14 No trial directly compared simple
patient referral with patient referral using contact
cards (see figure on www.ispm.ch/index.php?
id=1193). All trials had methodological limitations
and reporting quality was poor.
Strengths and weaknesses
Our review included studies of both women and men
with a range of curable sexually transmitted infections
in developed and developing countries. We searched
multiple databases and reference lists so it is unlikely
that we missed relevant controlled trials. We mini-
mised subjectivity by carrying out study selection,
data extraction, and quality assessment in duplicate
and used validated, replicable criteria for quality
assessment.13 Our conclusions were, however, limited
by the quality of included studies and the information
Kissinger et al 2005w2
Kissinger et al 2006w1
Overall (I 2=0%, P=0.44)
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Fig 3 | Randomeffectsmeta-analysis of secondary outcome in trials comparing patient delivered
partner therapywith patient referral supplemented by information for partners. Both trials had
unclear or inadequate concealment of allocation
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provided. Despite the large overall number of partici-
pants, differences in the interventions and outcomes
limited the use of meta-analysis to summarise results
and explore heterogeneity. Also our results apply
only to sexually transmitted infections that cause ure-
thritis, cervicitis, and vaginitis because we did not find
any relevant trials including patients with syphilis,
HIV, or other sexually transmitted infections.
Comparison with previous research
The new strategies identified in our review involved
methods that made it easier for the index patient to
share responsibility for the careof their sexual partners.
Traditionally partner notification has emphasised the
duty of confidentiality to the index patient, even if this
deters partners from seeking treatment.17 Observa-
tional evidence has suggested that providing more
information about the sexually transmitted infection
is acceptable to both index patients and partners.17
We identified seven randomised trials investigating
patient delivered partner therapyw1-w6 or home
sampling,w8 and two trials in resource poor
settingsw5 w9 that have not been included in previous
reviews.4 11 12 A narrative review of US trials of expe-
dited partner therapy, which is the term used in the
United States for any method that aims to speed up
treatment for sex partnerswithout an interveningmed-
ical evaluation or counselling, reached conclusions
similar to ours.18
Effectiveness of methods to enhance patient referral
Our review shows that the primary outcome in future
trials of partner notification should be a reduction in
infection rates because surrogate end points might be
misleading. Patient delivered partner therapy was
superior to simple patient referral for both biological
and behavioural outcomes. However, when patient
delivered partner therapy was compared with patient
referral in which index patients were also given infor-
mation for their sexual partners and treatment guide-
lines for the doctor, an increase in the numbers of part-
ners treated did not translate into a reduction in
persistent or recurrent infections.w1w2 It is possible
that the benefits of supplemented patient referral fol-
low frommore careful ascertainment of sexual contact
histories and extra discussion about the infection,
rather than the use of contact cards, which are rarely
returned.19 This is supported by the finding that when
simple patient referral included contact cards for index
cases, most trials providing further written or verbal
information did not show an increase in the numbers
of sexual partners treated.w12-w14 Patient delivered
partner therapywas beneficial in patients with chlamy-
dia, gonorrhoea, and syndromic diagnoses,w2-w5 but
not in women with trichomonas.w1 The reasons for
this are not clear.
Implications for research and practice
The number of doctors who practise patient delivered
partner therapy is increasing.7 20 21 According to the
Medicines and Healthcare Regulatory Authority simi-
lar strategies are legal in the United Kingdom if the
partner is assessedby a health professional. This assess-
ment can be done by telephone or by pharmacists sup-
plying the drugs. An intervention to accelerate partner
therapy in the United Kingdom is being developed
(C Estcourt, personal communication, 2006). Provid-
ing patients diagnosed as having chlamydia with self
sampling kits for their partners is also being evaluated
in a UK based randomised controlled trial
(ISRCTN12617257). Patient delivered partner ther-
apy also improved outcomes for syndromically diag-
nosed infections inUganda,w5 a resource poor country
where elaborate interventions are not feasible.3 22 The
poor specificity of syndromic management algorithms
inwomen, however, exposes them to the risk of gender
based violence.3 Trials in Africa were the only ones in
our review to have reported on the adverse effects of
partner notification. Strategies to improve the effec-
tiveness of patient referral for syphilis andHIV should
also be evaluated to expand the options available to
patients with these infections.
Future randomised trials of partner notificationmust
follow agreed standards of conduct and reporting.23
More than 10 years have passed since the consolidated
standards of reporting trials statement was first
published,24 but even the most recent trials in this
review did not report essential methodological details
such as methods of randomisation and allocation con-
cealment. When the sequence of randomisation was
clearly not concealedw2 imbalances between groups
in the numbers of participants suggest that allocation
was not truly random and that the benefit of the inter-
ventionmight have been overestimated. Furthermore,
the benefits of patient delivered partner therapy might
have been exaggerated by differences in the content of
interventions or ascertainment of outcomes. In five
trials indexpatients in the experimental group received
additional materials,w1-w4 including condomsw3 or
reimbursements,w5whichwere not given to the control
group.
Conclusion
Involving index patients in shared responsibility for
the management of sexual partners improves out-
comes. Health professionals should consider the fol-
lowing strategies for the management of individual
patients: patient delivered partner therapy, home sam-
pling for partners, and providing additional informa-
tion for partners.
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WHAT IS ALREADY KNOWN ON THIS TOPIC
The stigma attached to sexually transmitted infections makes partner notification difficult
Patient referral is preferred by patients and doctors for most curable sexually transmitted
infections
WHAT THIS STUDY ADDS
Involving index patients in the care of sexual partners improves the outcomes of partner
notification for chlamydia, gonorrhoea, and non-specific urethritis
Patient delivered partner therapy, home sampling, and additional information for partners
are more effective than simple patient referral
Simple patient referral combined with additional information for partners might be as
effective as patient delivered partner therapy
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